Cedilla Therapeutics, an oncology biotech founded by a former Editas executive, has snagged an additional $25 million to bring two small-molecule oncology programs into human trials.. The ...

About Cedilla’s CDK2 Program CDK2 (cyclin dependent kinase 2) has been a major target of interest for cancer indications driven by amplification or high levels of Cyclin E, including in roughly ...

Based on the screenshot shared by the Twitter user, diacritic suggestions will pop up when you long-press a key, illustrated below with the letter 'c' — in this case, a cedilla (ç).

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in... Contact Us. Contact Us.

Bayer BAYRY has announced an exclusive license agreement with Cedilla Therapeutics to jointly develop and commercialize the latter’s CyclinE1/CDK2 complex inhibitors for targeted oncogenic ...

Third Rock-founded Cedilla launches with $56.2 million to tackle protein stability The biotech firm will first go after tough oncology drug targets by Lisa M. Jarvis ...

Cedilla is also eligible to receive tiered royalty payments from Bayer on medicines based on the former’s technology commercialized by Bayer. In the year so far, shares of BAYRY have gained 8.7% ...